Epigenic Therapeutics, a Shanghai-based biotech company specializing in gene modulation therapy through epigenome regulation, has successfully raised USD 32 million in a Series A financing round. The round was co-led by Qiming Venture Partners and OrbiMed, with participation from existing investor Morningside Venture Capital. The funds will be utilized to support the preclinical development and early clinical validation of two leading programs, the discovery of future pipelines, the expansion of the leadership team, and continued investments in the company’s core technology platforms.
EPIREG Technology: A Safer Alternative to Gene Editing Tools
Epigenic boasts its proprietary EPIREG technology, which presents a compelling alternative to traditional cleavage-dependent gene editing tools. These traditional tools, which alter the DNA sequence, can raise safety concerns. In contrast, EPIREG precisely modulates gene expression at the epigenetic level, offering a safer approach to gene regulation. This technology is expected to achieve potent and durable silencing of target genes, providing revolutionary and novel solutions for patients suffering from chronic diseases.
Implications for Chronic Disease Treatment
The success of this funding round positions Epigenic Therapeutics to advance its innovative therapies, potentially transforming the treatment landscape for chronic diseases. By focusing on epigenetic regulation, the company aims to offer new hope to patients through its non-invasive and potentially safer gene modulation therapies.-Fineline Info & Tech
